Clearmind completes enrollment for CMND-100 trial part C

Clearmind Medicine (CMND) completed patient enrollment for Part C of its Phase I/IIa trial for CMND-100, a treatment for neuropsychiatric and addiction disorders. The trial, conducted in the U.S. and Israel, assesses safety, tolerability, and pharmacokinetics. The company aims to develop non-hallucinogenic psychedelic-derived compounds.

Original reporting
Published Nov 16, 2026, 12:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CMND
Bullish
high confidence
Mentioned
$CMND
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CMNDBullishMed
01

Why it matters

The enrollment milestone de‑riskes the CMND‑100 program, likely prompting short‑term buying interest.

02

Market read

A biotech milestone that can shift CMND's valuation and influence sector sentiment.

03

What to watch

Potential regulatory delays or competition from other psychedelic biotech firms.

Relevance 8/10Novelty 8/10Timing: today

Background

Clearmind Medicine focuses on non‑hallucinogenic psychedelic compounds for neuropsychiatric and addiction disorders.

Company-level read

Ticker impact

$CMNDBullishHigh confidence
Context

Clearmind Medicine announced completion of patient enrollment for Part C of its CMND-100 Phase I/IIa trial, a new corporate milestone.

Expected impact

likely upward pressure as the market prices in reduced trial uncertainty

Evidence & confidence

Milestone data is material for biotech valuations; investors often bid the stock on successful enrollment.

Market effects

May lift sentiment for the psychedelic‑derived therapeutics sector.

Limited to US and Israeli biotech markets.

Modest; primarily affects CMND and peers in the neuropsychiatric biotech space.

Counterpoint

If the trial later fails to show efficacy, the enrollment news could be a false positive.

Key entities

  • Clearmind Medicine Inc.

    Clinical‑stage biopharma developing CMND‑100.

  • Adi Zuloff‑Shani

    CEO of Clearmind Medicine.

Related articles

$CMNDLow

Clearmind completes patient recruitment for AUD trial segment

Clearmind Medicine (NASDAQ:CMND) completed patient recruitment for the first segment of Part B in its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. The trial, involving 12 patients, will assess safety, tolerability, and early efficacy signals. Sites include Johns Hopkins, Yale, and Israeli medical centers. According to the company, this marks a significant step in evaluating CMND-100 in the target patient population.

$CMNDLow

Clearmind has recruited its first group of people with alcohol use disorder for a clinical trial.

Clearmind Medicine (Nasdaq: CMND) has completed patient recruitment for the first segment of Part B of its Phase I/IIa clinical trial for CMND-100, a potential treatment for alcohol use disorder (AUD). The trial, conducted at sites including Johns Hopkins and Yale, will assess safety, tolerability, and early efficacy signals in patients with moderate-to-severe AUD. According to the company, this marks a significant milestone in validating CMND-100's therapeutic potential.

$CMNDMedAI 8/10

Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

$CMNDMed

Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

$CMNDMed

Clearmind Tumbles on Buying into Charging Robotics

Clearmind Medicine (CMND) agreed to buy a 51% stake in Charging Robotics, a wireless EV charging solutions provider, for $2.5M. The company will also lend Charging Robotics $1.5M at 4% interest. Charging Robotics' tech offers up to 10 kW continuous charging for automated parking and autonomous vehicles.